Kostas Biliouris
Stock Analyst at Oppenheimer
(0.64)
# 4,306
Out of 5,184 analysts
453
Total ratings
37.8%
Success rate
-1.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRME Prime Medicine | Reiterated: Buy | $11 | $3.55 | +209.86% | 21 | Nov 13, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $9 | $1.04 | +765.38% | 5 | Nov 13, 2026 | |
| LEGN Legend Biotech | Reiterated: Hold | $40 → $25 | $15.25 | +63.93% | 61 | Nov 11, 2026 | |
| DTIL Precision BioSciences | Reiterated: Buy | $20 | $7.40 | +170.27% | 23 | Nov 10, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Buy | $35 | $13.33 | +162.57% | 39 | Nov 6, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $350 → $320 | $143.82 | +122.50% | 42 | Nov 5, 2026 | |
| DYN Dyne Therapeutics | Downgraded: Hold | $15 | $15.50 | -3.23% | 6 | Oct 28, 2026 | |
| KRRO Korro Bio | Reiterated: Buy | $22 | $12.18 | +80.62% | 20 | Oct 28, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $20 | $3.99 | +401.25% | 4 | Oct 21, 2026 | |
| NRIX Nurix Therapeutics | Reiterated: Buy | $28 → $32 | $12.85 | +149.03% | 3 | Oct 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.78 | +296.83% | 4 | Oct 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $26 | $7.04 | +269.32% | 4 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $4.35 | +428.74% | 5 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $2.20 | +309.09% | 2 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57.37 | $8.24 | +596.23% | 3 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $9.02 | +132.82% | 4 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $76.03 | n/a | 12 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $20.90 | n/a | 23 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $60.41 | n/a | 31 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.23 | n/a | 30 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $26.58 | n/a | 27 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.69 | n/a | 4 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.565 | n/a | 9 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.00 | n/a | 25 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.95 | n/a | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $19.81 | n/a | 14 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $39.10 | n/a | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.97 | n/a | 6 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $77 | $286.85 | n/a | 1 | Jun 16, 2022 |
Prime Medicine
Nov 13, 2026
Reiterated: Buy
Price Target: $11
Current: $3.55
Upside: +209.86%
ProQR Therapeutics
Nov 13, 2026
Reiterated: Buy
Price Target: $9
Current: $1.04
Upside: +765.38%
Legend Biotech
Nov 11, 2026
Reiterated: Hold
Price Target: $40 → $25
Current: $15.25
Upside: +63.93%
Precision BioSciences
Nov 10, 2026
Reiterated: Buy
Price Target: $20
Current: $7.40
Upside: +170.27%
Sarepta Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $35
Current: $13.33
Upside: +162.57%
Alnylam Pharmaceuticals
Nov 5, 2026
Reiterated: Buy
Price Target: $350 → $320
Current: $143.82
Upside: +122.50%
Dyne Therapeutics
Oct 28, 2026
Downgraded: Hold
Price Target: $15
Current: $15.50
Upside: -3.23%
Korro Bio
Oct 28, 2026
Reiterated: Buy
Price Target: $22
Current: $12.18
Upside: +80.62%
Opus Genetics
Oct 21, 2026
Reiterated: Buy
Price Target: $20
Current: $3.99
Upside: +401.25%
Nurix Therapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $28 → $32
Current: $12.85
Upside: +149.03%
Oct 7, 2026
Reiterated: Buy
Price Target: $15
Current: $3.78
Upside: +296.83%
Sep 9, 2026
Reiterated: Buy
Price Target: $50 → $26
Current: $7.04
Upside: +269.32%
Sep 3, 2026
Reiterated: Buy
Price Target: $23
Current: $4.35
Upside: +428.74%
Aug 14, 2026
Reiterated: Buy
Price Target: $9
Current: $2.20
Upside: +309.09%
Aug 14, 2026
Reiterated: Buy
Price Target: $57.37
Current: $8.24
Upside: +596.23%
Jun 15, 2026
Reiterated: Buy
Price Target: $21
Current: $9.02
Upside: +132.82%
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $76.03
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $20.90
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $60.41
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $10.23
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $26.58
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $8.69
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $0.565
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $10.00
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $1.95
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $19.81
Upside: n/a
Sep 23, 2025
Reiterated: Buy
Price Target: $75
Current: $39.10
Upside: n/a
Jan 29, 2024
Rated: Hold
Price Target: n/a
Current: $2.97
Upside: n/a
Jun 16, 2022
Initiated Coverage: Buy
Price Target: $77
Current: $286.85
Upside: n/a